Latest news
From the Bench: Strategies to Inhibit KRAS, Enhance ADCs, and More | Blog | AACR - American Association for Cancer Research (AACR)American Association for Cancer Research (AACR) · Fri, 31 Jul 2026 13:00:34 GMTVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer - Business WireBusiness Wire · Tue, 28 Jul 2026 07:00:00 GMT